B and C); connection and RNase H domain resistance to reverse transcriptase inhibitors (including the effect of mutations in those domains on response to efavirenz and etravirine); resistance to hepatitis C virus and HIV-1 protease inhibitors; resistance to the integrase inhibitor raltegravir; global resistance epidemiology (including models to predict response to second-line antiretrovirals in resource-poor settings); and the role of minority resistant variants (including the effect of such variants on prevention of mother-to-child transmission of HIV-1). This report summarizes data from the oral abstract presentations at the workshop.
All oral and poster presentations at the XVIII International HIV Drug Resistance Workshop were selected by reviewers blinded to the names and affiliations of abstract authors. Reviewers abstained from scoring submitted abstracts if they perceived a conflict of interest or believed they did not have appropriate expertise. To rank abstracts, reviewer scores were averaged, standard deviation was calculated, and outlier scores were eliminated. A section on the global epidemiology of resistance was added to the XVII workshop, and a section on viral persistence, reservoirs, and elimination strategies was reinstituted.
Introduction
emerges in some patients controlling HIV-1 replication with antiretrovirals for several years [2] .
Although HIV-1 diversity tends to be low early in the course of infection and increases with disease progression, the effect of successful antiretroviral therapy on diversity of the virus remains poorly characterized. To monitor evolution of viral diversity during suppressive therapy, Kearney et al. [1] determined average pairwise difference in aligned sequences before therapy began and after treatment suppressed plasma viraemia to <75 HIV-1 RNA copies/ml in 10 patients and 6 monkeys. In the humans, the investigators analysed 1,143 gag-pro-pol sequences from 112 samples, 22 of them collected before treatment. In monkeys, they analysed 1,544 pol sequences from 69 samples, 18 of them collected before treatment. The investigators also determined relationships of viral subpopulations within individual patients by phylogenetic analysis.
In macaques infected with RT-SHIV (a chimeric simian immunodeficiency virus containing an HIV-1 reverse transcriptase [RT] ), average pairwise difference did not differ in a comparison of 18 pretreatment samples and 41 on-treatment samples (P=0.066) or in a comparison of on-treatment samples with 10 posttreatment samples (P=0. 19 ). In humans, intrapatient average pairwise distance ranged from 0.2% to 2.5% per site before therapy and did not change substantially during 1 year of fully suppressive therapy, despite up to a 10,000-fold decrease in HIV-1 RNA in plasma. Phylogenetic analysis disclosed no change in viral population structure after viral control with therapy.
In earlier work by Bailey et al. [2] , residual virus in plasma of patients taking suppressive antiretroviral therapy became dominated by a homogeneous population with identical pol sequences, although overall diversity in pol remained high in resting CD4 + T-cells. These so-called predominant plasma clones were released into the circulation for months to years with no measurable changes in pol sequences. Kearney et al. [1] identified a predominant plasma clone in one of their patients who maintained plasma viraemia <75 HIV-1 RNA copies/ml for 4 years. They suggested persistence of sequence diversity during treatment implies that antiretroviral resistance mutations pre-existing in the viral population of a patient are unlikely to be eliminated by antiretroviral therapy.
Intensification tactics do not reduce low-level HIV-1 viraemia
Adding raltegravir, efavirenz or a protease inhibitor (PI) to an antiretroviral regimen that already suppressed plasma viraemia to <50 copies/ml did not further lower HIV-1 RNA in plasma, according to results of several studies including a total of 19 patients [3] . The findings run counter to the hypothesis that persistent low-level plasma viraemia results from ongoing complete cycles of viral replication.
Approximately 80% of patients with plasma HIV-1 RNA below the 50 copies/ml limit of detection measured by standard assays have ≥1 copy/ml detectable by more sensitive assays. The level of this low-frequency viraemia does not vary by antiretroviral regimen, does not decay during long-term therapy, and increases before virological rebound. The source of persistent viraemia remains undetermined, though different investigators have suggested long-lived chronically infected cells, active cycles of HIV-1 replication, sanctuary sites of replication, or a combination of sources.
If persistent viraemia represents active cycles of replication, a more suppressive regimen should further lower plasma viraemia already below the limit of detection of standard assays. To evaluate that possibility, Maldarelli et al. [3] selected patients with HIV-1 RNA<50 copies/ml for at least 6 months while taking a regimen recommended by the US Department of Health and Human Services [4] . Everyone had >0.6 HIV-1 RNA copies/ml of plasma by a highly sensitive assay, a CD4 + T-cell count >200 cells/mm 3 , and no documented resistance to antiretrovirals. After 21 days of baseline HIV-1 RNA sampling, 10 patients added the integrase inhibitor raltegravir for 4 weeks, 2 added the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz for 4 weeks, 2 added the PIs lopinavir/ritonavir for 4 weeks and 5 added the PIs atazanavir/ritonavir for 8 weeks.
Median residual viraemia did not change significantly in the three study periods: before intensification, during intensification and after intensification. Among the 10 patients adding raltegravir, median viraemia stood at 0.17 log 10 copies/ml before intensification, 0.04 log 10 copies/ml during intensification (P=0.92 versus before), and 0.04 log 10 copies/ml after intensification (P=0.73 versus during). Low-level viraemia did not change significantly in any individual from one period to the next. All patients attained therapeutic concentrations of the intensification drug, and resistant virus did not emerge during the study. The investigators published partial results of this study immediately before the workshop [5] . Maldarelli et al. [3] concluded that active cycles of HIV-1 replication do not explain persistent low-level viraemia in patients taking a suppressive regimen.
CD8 + T-cell immune activation markers do not correlate with residual viraemia
Markers of CD8 + T-cell activation correlate with HIV-1 RNA in plasma before antiretroviral therapy [6, 7] ; however, the relation between CD8 + T-cell activation and residual viraemia during suppressive antiretroviral therapy remained unexplored until this study of 33 patients with plasma viraemia <50 HIV-1 RNA copies/ml for >3 years of treatment [8] . To determine whether persistent viraemia <50 HIV-1 RNA copies/ml correlates with immune activation markers on CD8 + T-cells, Cossarini et al. [8] conducted a case-control study of 33 HIV-1-infected individuals and 43 uninfected controls matched to cases for age, sex, and race. The HIV-1-infected patients maintained plasma viraemia <50 HIV-1 RNA copies/ml for >3 years on their first antiretroviral regimen, never interrupted their antiretrovirals, and had <2 transient viraemia rebounds >500 copies/ml. The investigators measured T-cell activation as expression of CD38 or HLA-DR on CD8 + T-cells, and they determined residual viraemia with a single-copy assay that has a sensitivity limit of 0.4 HIV-1 RNA copies/ml.
Plasma viraemia in HIV-1-infected patients fell from a median of 4.68 log 10 copies/ml before treatment to <1.69 log 10 copies/ml after 1, 4 and 7 years of therapy (P<0.01 compared with before treatment). During that time, median CD8 + T-cell count remained stable (680 cells/mm 3 before therapy and 641 cells/mm 3 after 7 years). CD8 + CD38 + T-cells decreased significantly from pretreatment values (P<0.0001 during months 0 to 48), but levels stabilized after 48 months. The same pattern held true for CD8 + HLA-DR + T-cells. During long-term suppressive therapy, there were no significant differences between HIV-1-infected individuals and healthy uninfected controls in proportions of activated CD8 + CD38 + or CD8 + CD38 + HLA-DR + subsets (P=0.254 and P=0.325, respectively). Percentage of CD8 + CD38 + T-cells correlated positively with plasma HIV-1 RNA before treatment (r=0.40, P=0.03). However, there was no correlation between activation markers and persistent low-level viraemia during treatment (r=0.119 for CD38, r=0.095 for HLA-DR and r=0.294 for CD38 and HLA-DR). Cossarini et al. [8] concluded that residual low-level viraemia on antiretroviral therapy might not be a sufficient stimulus to maintain the increased CD8 + T-cell activation seen in patients with uncontrolled viraemia.
2-LTR HIV-1 DNA levels do not change during 24 weeks of raltegravir
Among patients who maintained plasma viraemia <400 HIV-1 RNA copies/ml on a regimen including raltegravir or enfuvirtide in the EASIER trial [9] , total DNA and circularized DNA (measured as 2-LTR circles) did not evolve through 24 weeks of follow-up [10] .
After retrotranscription of HIV-1 RNA, different HIV-1 DNA forms have been described: linear DNA, DNA integrated in the host cell genome (so-called provirus), and circular extrachromosomal DNA with 1-and 2-LTR (so-called episomal or 2-LTR circles). Total DNA consists of circularized DNA, linear DNA and integrated DNA. In vitro, integration inhibition leads, first, to increased extrachromosomal forms and, second, to absence of detectable integrated DNA.
Delaugerre et al. [10] hypothesized that an agent that blocks integration of virus into the host cell genome in vivo, such as raltegravir, would lead eventually to lower HIV-1 DNA levels in cell reservoirs and that measuring 2-LTR DNA circles would be a useful way to determine raltegravir activity in patients with undetectable plasma viraemia.
EASIER randomized highly treatment-experienced patients with <400 HIV-1 RNA copies/ml while taking an enfuvirtide-containing regimen either to continue that regimen or to exchange enfuvirtide for raltegravir. After 24 weeks, switching to raltegravir was not inferior to continuing enfuvirtide, as nearly 90% in each treatment arm maintained plasma viraemia <50 HIV-1 RNA copies/ml [9] . For the DNA study, Delaugerre et al. [10] measured 2-LTR circles and total HIV-1 DNA on day 0 and at week 24 in the first 30 EASIER enrolees randomized to continue enfuvirtide and the first 30 randomized to raltegravir.
Median total DNA copies/10 6 peripheral blood mononuclear cells (PBMCs) remained essentially unchanged through 24 weeks of treatment in both the raltegravir group and the enfuvirtide group (P=0.71). Two patients randomized to continue enfuvirtide and four who switched to raltegravir had HIV-1 2-LTR circle levels >20 copies/10 6 PBMCs on day 0. At week 24, three different patients, two taking enfuvirtide and one taking raltegravir, had 2-LTR circle levels >20 copies/10 6 PBMCs. Delaugerre et al. [10] concluded that total HIV-1 DNA does not evolve during 6 months of raltegravir therapy and that HIV-1 2-LTR DNA appears not to be a sensitive marker of raltegravir activity in patients with undetectable plasma viraemia.
Greater viraemia variability in elite controllers versus treated patients Interpatient variability in low-level viraemia proved greater among elite controllers (who maintain plasma viraemia <50 HIV-1 RNA copies/ml without treatment) than among antiretroviral-treated patients in a longitudinal comparison [11] . However, mean low-level viraemia was not statistically different in the two study groups.
Palmer et al. [11] used a real-time RT-PCR singlecopy assay that measures viral RNA down to a single copy in 3 ml of plasma in three groups: 85 elite controllers with <50 HIV-1 RNA copies/ml at least three times over 12 months, infrequent spikes in viraemia always <500 copies/ml, and infection duration ranging from 9 to 19 years; 158 patients maintaining plasma HIV RNA<50 copies/ml while taking a regimen containing lopinavir/ritonavir, nelfinavir or an NNRTI; and 163 patients with HIV-1 RNA<50 copies/ml at all visits from week 96 to weeks 340-384 while taking lopinavir/ ritonavir plus stavudine/lamivudine in a 7-year trial.
In the antiretroviral-treated patients, the singlecopy assay determined that 77% of samples had viraemia detectable at >1 HIV-1 RNA copy/ml [12] . By comparison, approximately 75% of elite controllers had measurable low-level viraemia. In a crosssectional analysis, mean viraemia values did not differ significantly between patients on suppressive therapy (0.50 log 10 copies/ml, or 3 copies/ml) and all elite controllers (0.49 log 10 copies/ml; P=0.95). However, between-patient variability was much greater among elite controllers than among those controlling HIV-1 with antiretrovirals (P<0.0001).
Longitudinal analysis involving 441 data points from 117 patients on suppressive therapy and 24 elite controllers confirmed the wider between-patient variability in plasma viraemia among elite controllers than treated patients. This analysis also showed significantly wider within-patient variability in the elite controllers than in treated patients (sd 0.60 versus 0.38; P<0.0001). Whether the greater interpatient and intrapatient variability among elite controllers reflects the smaller sample of controllers versus treated people arose as a question after presentation of these findings.
Palmer et al. [11] proposed that spontaneous changes in low-level viraemia in elite controllers indicate ongoing rounds of viral replication and immune suppression.
HIV-1-specific CD4 + T-cells might contribute to viral persistence in elite controllers
Although HIV-1-specific CD4 + T-cells might contribute to viral suppression in elite controllers, results of a 38-person study suggest [13] that they might also provide a reservoir of viral targets that permit ongoing replication and persistent low-level viraemia in these individuals.
Hunt et al. [13] defined elite controllers as individuals with <75 HIV-1 RNA copies/ml of plasma without therapy. They noted that elite controllers also maintain stably low proviral HIV-1 DNA levels in PBMCs, often 10-fold lower than in patients with antiretroviral-suppressed viraemia. Although proviral DNA in PBMCs of elite controllers appears to remain stable over time [14] , viral evolution can be detected in peripheral blood of many elite controllers [15] .
Hypothesizing that the viral reservoir in elite controllers is continually replenished by HIV-1-specific CD4 + T-cells, Hunt et al. [13] assessed the association between plasma and cellular reservoirs in elite controllers and three host responses: percentage activated (CD38  + HLA-DR  + ) CD4  + and CD8  + T-cells, percentage HIV-1 Gag-specific CD4  + and CD8  + T-cells, and  percentage cytomegalovirus pp65-specific CD4  + and  CD8 + T-cells. The investigators used the GenProbe transcription-mediated amplification assay to measure plasma and cell-associated HIV-1 RNA. + T-cells was not associated with cellassociated HIV-1 RNA or proviral DNA.
Next Hunt et al. [13] asked whether activated HIV-1 -specific CD4 + T-cells are replenishing the reservoir of infected cells, or if higher cell-associated HIV-1 RNA production is causing general induction of immune activation and HIV-1-specific immune responses. If the second possibility were true, one would expect to see strong associations between CD8 + T-cell activation and HIV-1-specific CD8 + T-cell responses. However, cell-associated HIV-1 RNA was not associated with percentage activated or HIV-1-specific CD8 + T-cells in these elite controllers. HIV-1 DNA in PBMCs was associated with percentage activated CD8 + T-cells (ρ=0.46, P=0.04), but not with HIV-1-specific CD8 + T-cells. Hunt et al. [13] proposed that, together, these findings suggest that strong HIV-1-specific CD4 + T-cell responses might contribute to viral persistence in elite controllers. The very immune response contributing to control of viral replication in these rare individuals might also be contributing to viral persistence.
Novel compound induces HIV-1 reactivation and receptor down-regulation SJ23B, a novel agent sharing some mechanisms with the phorbol ester prostratin, potently inhibited HIV-1 by down-regulating the viral receptors CD4, CCR5 and CXCR4 [16] . This agent also induces viral reactivation through transactivation of HIV-1 LTR. Reactivation of HIV-1 from latently infected cells is considered essential to viral eradication strategies.
SJ23B is a jatrophane diterpene derived from the plant Eurphorbia hiberna. Rullas et al. [17] planned experiments to determine whether the mechanisms of action of SJ23B are similar to those of phorbol esters, although the novel compound is structurally different from phorbol esters. The phorbol ester prostratin has two effects on the replication cycle of HIV-1: down-regulation of HIV-1 receptors and induction of viral transcription. In PBMCs activated by CD3 + interleukin-2 for 48 h, 2 h of exposure to SJ23B at a concentration of 0.1 or 1 µM down-regulated membrane expression of CD4, CCR5 and CXCR4. SJ23B had little or no effect on receptor expression on resting PBMCs.
Measuring antiviral activity as percentage inhibition of Renilla-luciferase units in activated PBMCs, the investigators determined that SJ23B had approximately 10-fold greater activity than prostratin. In Jurkat LAT-GFP cells exposed to SJ23B or prostratin, SJ23B had little or no effect on expression of other receptors such as MHC class I on resting PBMCs.
To further characterize potential reactivation of HIV-1 by SJ23B, Rullas et al. [17] transfected primary resting T-lymphocytes with either a full-length provirus, LTR or luciferase expression vectors under the control of consensus sequences for NF-κB, Sp1 and NF-AT transcription factors. These experiments showed that SJ23B activates transcription through activation of NF-κB and Sp1 in these cells.
Further work with isoform-specific protein kinase C, MEK and JNK inhibitors suggested that SJ23B activates classical protein kinase C. SJ23B did not induce transforming foci in NIH3T3 cells [18] .
New in vitro cell system contradicts earlier notions of HIV-1 latency A primary cell differentiation model developed by Bosque et al. [19] yielded findings that contradict ideas of HIV-1 latency arrived at by experiments using transformed cell lines. In the new system, naive CD4 + T-cells from the peripheral circulation of healthy donors are induced to undergo normal development through antigenic stimulation via CD3 and CD28 [20] . The cells can then be infected with HIV-1 while active and allowed to return to a quiescent state as memory cells. Ex vivo infection in this system leads to latency in approximately 90% of infections and to a polyclonal population of integrated species.
Using this system to explore the effect of signalling pathways on HIV-1 latency, Bosque et al. [19] found that viral reactivation after T-cell receptor engagement depends on activation by the tyrosine kinase Lck (upstream) and the transcription factor nuclear factor (NF)-AT (downstream). NF-κB is not required for reactivation, a finding that contradicts results of experiments in transformed cell lines. Measuring Ki-67 as a cell-proliferation marker allowed the investigators to determine that proliferation might occur frequently (in up to 41.8% of cells) in the absence of viral reactivation. Bosque et al. [19] proposed that cell-cycle entry is neither necessary for viral reactivation nor an impediment to reactivation and the latent reservoir is subject to homeostatic expansion.
Gene that might drive chronic HIV-1 activation is identified
Chitinase-3-like-1 (CHI3L1) might play a role in facilitating bacterial translocation from the gut [21] , a process implicated in the chronic immune activation that contributes to HIV-1 disease progression [22] . Because earlier work showed that CHI3L1 can exacerbate intestinal inflammation by enhancing bacterial adhesion and invasion of colonic epithelial cells [23] , Smith et al. [21] planned a series of experiments to confirm CHI3L1 expression in gut tissue and to assess the ability of CHI3L1 to participate in microbial translocation.
Measuring CHI3L1 expression in ileal and rectal biopsies from patients with acute HIV-1 infection, presymptomatic infection, or AIDS, and from uninfected controls, the investigators found the highest expression in acute infection (approximately 12-fold versus controls; P=0.0042) and lower levels in presymptomatic and advanced infection, though levels in the latter two groups remained significantly higher than in controls (approximately 8-fold versus controls). Antiretroviral therapy significantly decreased CHI3L1 expression in HIV-1-infected gut. Viral replication correlated positively and significantly with CHI3L1 expression (r=0.4433, P=0.0071).
To determine whether CHI3L1 is involved in bacterial translocation, Smith et al. [21] expressed CHI3L1 in HT-29 enterocytes, an intestinal epithelial cell line, and measured levels of bacterial internalization. CHI3L1 significantly promoted internalization of Salmonella typhimurium compared with the control assay (P=0.0001). Anti-CHI3L1 antibody significantly decreased S. typhimurium internalization, bringing internalized bacteria levels back down to those recorded in the control assay. The investigators saw similar effects in internalization assays using Escherichia coli. In vivo, translocated bacteria in HIV-1-infected gut tissue localized spatially with CHI3L1-expressing cells.
Smith et al. [21] determined whether CHI3L1 expression is linked to immune activation by measuring expression of a cell-activation marker, Ki-67, in inguinal lymph nodes. They found a strong positive correlation between Ki-67 messenger RNA expression and CHI3L1 expression in gut tissue (r=0.8488, P<0.0001). Expression of the activation marker CD38 in inguinal lymph nodes also correlated with CHI3L1 expression (r=0.7358, P<0.0001).
Resistance to HIV-1 entry inhibitors
HIV-1 RNA reduction is similar after screening with Trofile or genotypic algorithm
Although genotypic systems to infer HIV-1 coreceptor use had poor sensitivity in predicting phenotypically determined coreceptor use in a maraviroc trial analysis, if trial participants had been screened with the genotypic systems, they would have had nearly identical short-term virological responses to those recorded after phenotypic screening in the actual trial [24] .
MOTIVATE-1 randomized highly treatmentexperienced patients to the CCR5 antagonist maraviroc plus an optimized background regimen or to placebo plus optimized background regmen [25] . This retrospective analysis by Harrigan et al. [24] also considered patients in a sister trial, A4001029. MOTIVATE-1 relied on the original Trofile phenotypic assay to exclude patients with CXCR4-using virus. A subset of these patients with non-R5 virus entered the A40001029 trial.
Triplicate V3 loop screening was performed on stored viral samples, and those sequences were analysed by two genotypic interpretation systems, geno2pheno (with a 5% false-positive rate) and PSSM (with a -2.96 cutoff), to infer coreceptor use. The analysis involved 1,230 samples, 533 of which were designated CXCR4-using by the original less sensitive Trofile assay. The genotypic algorithms had sensitivities of only 63% (geno2pheno) and 56% (PSSM) in identifying virus designated as CXCR4-using by Trofile. However, when the investigators compared 8-and 12-week virological responses in patients according to coreceptor assignment by Trofile, geno2pheno, or PSSM, they found only minor differences (Table 1) .
Among patients treated with twice-daily maraviroc, sensitivity for predicting 8-week antiviral activity (<50 HIV-1 RNA copies/ml or >2 log 10 HIV-1 RNA reduction) was 90% with Trofile, 85% with geno2pheno, and 87% for PSSM. Sensitivity remained high with all three methods in a 24-week response analysis (<50 HIV-1 RNA copies/ml): 90% with Trofile, 81% with geno2pheno, and 86% with PSSM. Specificity in predicting 8-or 24-week activity was low for all three tests because antiretroviral regimens might fail for several reasons besides coreceptor use.
Four mutations required for resistance to vicriviroc in one clinical isolate
A site-directed mutagenesis study evaluating seven amino acid changes detected in a subtype D virus upon failure of vicriviroc determined that four of those mutations are necessary to confer complete resistance to this CCR5 antagonist [26] . This combination of mutations resulted in increased dependence on viral envelope interaction with the N terminus of CCR5 for viral entry.
Clinical failure of CCR5 antagonists can involve classic emergence of mutations conferring resistance or emergence of pre-existing CXCR4-using virus not detected before treatment. To better characterize resistance to vicriviroc, Howe et al. [26] analysed viral constructs derived from a subtype D virus that continued to use CCR5 throughout vicriviroc treatment and failure. Pseudovirus generated with a pretreatment chimeric clone containing the CCR5 binding domain of this virus was completely susceptible to vicriviroc, whereas the cognate week-48 pseudovirus was fully resistant to the drug.
The investigators rebuilt the resistant phenotype in the pretreatment envelope by adding back the resistance mutations present at failure. Individual mutations and pairs proved insufficient to affect viral susceptibility to vicriviroc, and most of these single mutants had reduced infectivity when compared with the non-mutant pretreatment clone. Three mutations had to be combined before virus became partially resistant to vicriviroc, and four mutations were required to confer nearly complete resistance. However, this quadruple mutation combination was found in no clones derived from virus of the patient in whom vicriviroc failed. All seven mutations in the CCR5 binding site were needed to replicate the resistant phenotype characterized at vicriviroc failure.
To analyse mutations in the context of CCR5 binding, Howe et al. [26] used a recently developed model that predicts how the N terminus of CCR5 interacts with the binding pocket formed by the base of the V3 loop and amino acids from the bridging sheet domain [27] . The investigators made a series of CCR5 mutations to reflect crucial viral contacts with gp120 residues. They found that cells expressing CCR5 with a deletion of residues 2-17 in the receptor N terminus inhibited infection of pseudovirus containing both baseline and resistant envelopes. This finding demonstrated that the N terminus is crucial for viral entry of both the baseline and resistant chimeras.
Analysis of the effect of individual point mutations suggested that the resistant clone becomes more dependent on the N-terminal interaction with CCR5 for viral entry. Discovery of two new interactions between resistant gp120 and CCR5 suggested that the resistant phenotype in the subtype D patient could form a higher affinity interaction with the N terminus of CCR5. Howe et al. [26] proposed that their findings suggest a high barrier to resistance to vicriviroc, which might explain infrequent or slowly developing classical resistance to this agent in clinical trials. Lively discussion about this conclusion ensued.
Differing resistance mechanisms with three CCR5 antagonists
PSC-RANTES and maraviroc inhibit HIV-1 replication by different mechanisms and, as a result, differing resistance mechanisms explained decreased susceptibility to these agents in studies employing primary HIV-1 isolates with varying susceptibility to PSC-RANTES, maraviroc, and TAK-779 [28] . TAK-779 (a small-molecule CCR5 antagonist no longer in development) and maraviroc (the only currently licensed CCR5 antagonist) bind to a hydrophobic cavity created by two transmembrane helices of CCR5. RANTES is a natural ligand of CCR5. The chemokine analogue PSC-RANTES engages the second extracellular loop of CCR5 and down-regulates CCR5 expression. But viral inhibition by PSC-RANTES appears to be mediated by competitive binding to CCR5.
Earlier research linked variable sensitivity to PSC-RANTES to discrete polymorphisms in the V3 loop of HIV-1 gp120. Introducing these polymorphisms into a neutral HIV-1 backbone increased sensitivity to PSC-RANTES, and that increased sensitivity correlated with replicative fitness [29] . Sensitivity to TAK-779 and maraviroc, by contrast, did not strongly correlate with replicative fitness. In vitro selection of resistance to maraviroc results in virus of variable fitness that can often use CCR5 already bound by the inhibitor.
Lobritz et al. [28] hypothesized that PSC-RANTES inhibits HIV-1 primarily through a competitive mechanism and that, as a result, the level of resistance will relate to CCR5 receptor affinity (a direct correlate of fitness). By contrast, they proposed, maraviroc and other CCR5 antagonists inhibit HIV-1 through a non-competitive mechanism; thus, levels of resistance to these agents should correlate poorly with fitness and entry efficiency.
A panel of primary HIV-1 isolates, including subtypes A, B, C and D had approximately a 100-fold variation in susceptibility to maraviroc as measured by the 50% inhibitory concentration (IC 50 ). The same panel of isolates had only an approximately fivefold variation in susceptibility to PSC-RANTES. Pairwise competition analyses to determine replicative fitness of primary isolates defined a transitive relationship for all but two of the 84 pairwise competitions, a result suggesting that a dominant gene or trait controls replicative fitness. This finding supports previous work indicating that fitness of primary HIV-1 isolates is controlled by the efficiency of host cell entry and maps predominantly to the env gene [30] .
Maraviroc IC 50 correlated poorly with relative fitness of primary isolates (r=0.25, P=0.38). However, Lobritz et al. [28] found a significant positive correlation between PSC-RANTES IC 50 and fitness (r=0.52, P<0.04). With PSC-RANTES concentrations held constant, PSC-RANTES IC 50 values increased with increased substrate (HIV-1) concentration. By contrast, IC 50 values for TAK-779 and maraviroc remained relatively unchanged as HIV-1 concentrations increased.
Lobritz et al. [28] concluded that maraviroc and TAK-779 inhibit HIV-1 by a non-competitive mechanism reflected in the lack of correlation between relative binding affinity of the virus to sensitivity to the inhibitor. With PSC-RANTES, the most important mechanism of inhibition is not down-regulation of CCR5 but competitive binding to this receptor. As a result, resistance to PSC-RANTES might be associated with increased binding to CCR5. As noted above, this increase in CCR5 affinity also relates to increased entry efficiency and, as a consequence, increased fitness.
Multiple mutation pathways lead to CXCR4 coreceptor use
Analysis of emerging CXCR4 coreceptor-using virus in eight patients not taking antiretrovirals showed that HIV-1 can take multiple routes in changing coreceptor preference from CCR5 to CXCR4 [31] . The study by Huang et al. [31] involved longitudinal plasma-derived viruses from eight antiretroviral-naive individuals with documented evolution from non-syncytium-inducing (CCR5-using) virus to syncytium-inducing (CXCR4-using) virus in the Amsterdam HIV cohort. Huang et al. [31] isolated envelope clones from different time points for each person, determined coreceptor use with the Trofile phenotypic assay and analysed envelope sequences with conventional methods. Viral populations at the time when CXCR4-using virus began to emerge consisted of mixtures of R5 clones and dual clones (which use CCR5 and CXCR4). The proportion of dual/mixed clones and their relative ability to use CCR5 and CXCR4 varied from person to person.
Huang et al. [31] identified two types of dual virus, which they designated dual-X virus (which uses CXCR4 efficiently) and dual-R virus (which uses CXCR4 inefficiently). All eight Amsterdam cohort members had dual-X clones and six also had dual-R clones. Dual-R clones appeared before or concurrently with dual-X clones.
Phylogenetic analysis of full-length envelope sequences showed that emerging dual-X variants had limited diversity and differed markedly from R5 and dual-R clones in some but not all individuals. Efficient CXCR4 use usually required multiple amino acid changes in the V3 loop, but Huang et al. [31] identified few discernable patterns from one individual to the next, and these mutations arose in different orders. In one patient, efficient CXCR4 use arose with no amino acid changes in V3.
Huang et al. [31] concluded that transitions from CCR5 to CXCR4 are incremental (not quantum) and are consistent with their proposed model of R5, dual-R and dual-X clones describing evolution of coreceptor use.
X4-related mutations after 11/25 change are mostly compensatory
Numerous mutations linked to emergence of CXCR4-using virus appear to be compensatory mutations that emerge to restore lost viral fitness conferred by the primary 11/25 mutations, 306R/K/H and 322R/K/H [32] . These findings by Thielen et al. [32] suggest little ongoing evolution toward X4 virus after 306R/K/H and 322R/K/H emerge.
Mutations in the V3 loop on gp120 largely determine coreceptor use of HIV-1. Whether mutations outside V3 precede the switch to CXCR4 use or compensate for fitness loss induced by V3 mutations remains unexplored. To address that question, Thielen et al. [32] constructed mutagenic trees [33] to model HIV-1 resistance pathways involving V3 and non-V3 mutations. They downloaded subtype B sequences from the Los Alamos database, selecting only one sequence per patient. This analysis included 9,557 V3 sequences, 2,656 V2 sequences, 2,098 C4 sequences and 827 gp41 sequences.
The investigators determined that mutations at 23 positions in V3, 15 in gp41, 13 in V2 and 2 in C4 were significantly associated with X4 virus (P<0.05). Almost all mutagenic trees showed 306R/K/H and 322R/K/H appearing in two different tree arms, a finding suggesting that these mutations represent independent pathways to evolution of CXCR4 use.
Other mutations at positions 306 and 316 usually preceded 306R/K/H. The other mutations analysed usually followed 306R/K/H and 322R/K/H. For example, the A/I/V insertion after position 515 in gp41, which predicts CXCR4 use, followed 306R/K/H, as did mutations disrupting the N-glycosylation motif of V3. The well known S195H mutation in V2 usually appeared after 322R/K/H. The CXCR4-related S440D/E mutation in C4 evolved independently of 306R/K/H and 322R/K/H.
Resistance to reverse transcriptase inhibitors: polymerase domain
Resistance to lamivudine emerges with hepatitis B virus DNA<12 IU/ml Mutations in hepatitis B virus (HBV) polymerase conferring resistance to lamivudine can emerge in patients with undetectable HBV DNA, according to results of a 64-patient study [34] .
Svicher et al. [34] sequenced virus from two groups: 25 patients receiving first-line lamivudine monotherapy and experiencing their first rebound in viraemia from 12 IU/ml to 345 IU/ml (69-2,000 HBV DNA copies/ ml), and 39 patients receiving first-line lamivudine in whom HBV viraemia remained <12 IU/ml. In the latter group, 24 patients were receiving lamivudine monotherapy and 15 were taking lamivudine plus adefovir. No patients had HIV-1 infection.
HBV sequencing succeeded in 22 of 25 (88%) samples with HBV viraemia between 12 and 345 IU/ml and in 12 of 39 (31%) with viraemia <12 IU/ml. A total of 8 of these 12 were taking lamivudine monotherapy and 4 were taking lamivudine plus adefovir. In the 22 patients in whom lamivudine failed, median viraemia in 17 (77%) patients with resistance mutations was significantly higher than in 5 patients without detectable mutations (2.0 versus 1.5 log 10 IU/ml; P=0.03). The most prevalent mutations were M204V (36.5%), M204I (31.8%), M204V/I (4.5%) and A181T (4.5%). These primary mutations occurred with at least two compensatory mutations in 63.6%.
Resistance mutations could be detected in 6 of 12 patients with HBV viraemia <12 IU/ml, including M204I in 3 patients, M204V in 2, and M204I plus V84M (an adefovir-related mutation) in 1. Mutations arose in 4 of 8 patients taking lamivudine monotherapy (versus lamivudine plus adefovir) and maintaining HBV viraemia <12 IU/ml.
Svicher et al. [34] concluded that the risk of virological failure with early development of cross-resistance to other anti-HBV agents should be considered when planning rational therapy for HBV-infected patients. They suggested that proactive switch strategies could sometimes be a strategic option.
MI84I/V evolves less with emtricitabine than with lamivudine
The M184I/V mutations evolved significantly less often with emtricitabine/tenofovir than with lamivudine/ tenofovir or lamivudine without tenofovir in a comparison involving 1,337 patients with HIV-1 infection [35] . Taking tenofovir or a ritonavir-boosted PI independently protected against emergence of M184I/V in this population.
Svicher et al. [35] determined resistance to emtricitabine or lamivudine in HIV-1 subtype B isolates from three groups: 168 patients taking emtricitabine/tenofovir, 249 taking lamivudine/tenofovir and 920 taking lamivudine without tenofovir. Median duration of virological failure stood at 14 weeks in the emtricitabine/tenofovir group, 16 weeks in the lamivudine/tenofovir group and 15 weeks in the lamivudine-only group (P=0.23). Prevalence of previous lamivudine exposure was >90% and statistically equivalent in the three groups. A significantly lower proportion of patients taking emtricitabine/ tenofovir took those drugs with an NNRTI (27.4%) than did patients taking lamivudine/tenofovir (37.7%) or lamivudine without tenofovir (39.0%; P=0.02). PI use was significantly higher in the emtricitabine/ tenofovir group (70.2% versus 47.8% and 48.5%; P<0.001).
Prevalence of M184I/V was significantly lower among patients taking emtricitabine/tenofovir than among those taking lamivudine/tenofovir or lamivudine without tenofovir ( Table 2 ). M184I/V prevalence remained lower with emtricitabine/tenofovir when Svicher et al. [35] stratified patients by use of NNRTIs versus PIs or failure of one or multiple regimens ( In vitro selection in CEM cells determined that emtricitabine/tenofovir did not select mutations at position 184 at emtricitabine concentrations up to 0.1 µM and tenofovir concentrations up to 1.25 µM. M184I did emerge at an emtricitabine concentration of 0.1 µM without tenofovir.
Svicher et al. [35] suggested that the higher prevalence of M184I/V with lamivudine than with emtricitabine could be attributed to greater potency of emtricitabine, different intracellular pharmacokinetics of emtricitabinetriphosphate versus lamivudine-triphosphate, or, in these patients, greater use of ritonavir-boosted PIs with emtricitabine/tenofovir.
In vitro study finds similar K65R emergence with subtypes C and B
In vitro selection experiments determined that the K65R RT mutation did not emerge more often in virus containing HIV-1 subtype C RT than in virus containing subtype B RT [36] . Dobard et al. [36] cautioned that their findings do not exclude the possibility that different selection conditions or viral regions other than RT might influence K65R selection in subtype C isolates.
An earlier study recorded selection of K65R by week 12 in subtype C isolates tested in cord blood mononuclear cell culture [37] . In the same experiments, K65R was not selected by week 72 in subtype B isolates. The faster emergence of K65R in subtype C isolates has been attributed to natural polymorphisms at RT positions 64 (AAG to AAA) and 65 (AAA to AAG) in subtype C that are not seen in subtype B. Previous work also found faster selection of K65R in recombinant subtype B viruses with subtype C nucleotide sequences at positions 64 and 65 than in subtype B isolates without those polymorphisms [38] .
Dobard et al. [36] compared the kinetics of K65R selection with tenofovir in subtype-B-based recombinant viruses carrying RT from subtype B or C isolates. They generated these recombinant viruses from six subtype B isolates and three subtype C isolates in a subtype B (HXB-2) backbone. The investigators selected K65R in MT4 cells by sequential passage of virus in the presence of increasing concentrations of tenofovir. They monitored emergence of K65R in culture supernatants by conventional sequencing and by a real-time PCR assay with a minority population detection limit of 0.4%.
Sequence analysis showed that all recombinant subtype C viruses harboured the signature polymorphisms at positions 64 and 65. All recombinant viruses were infectious and replicated well in the absence of drug. All six subtype B recombinants selected K65R in a median of four passages and a median of 45 days, at a median tenofovir concentration of 24 µM, generating sixfold resistance to tenofovir. All three subtype C recombinants selected K65R in a median of four passages and a median of 40 days, at a median tenofovir concentration of 24 µM, generating sevenfold resistance to tenofovir. In two of three subtype C virues, real-time PCR detected minority K65R variants one passage earlier than standard sequencing detected K65R.
FTC/TDF, n/total n (%) 3TC/TDF, n/total n (%) 3TC (TDF-naive), n/total n (%) P-value 
Q151L mutation selected by GS-9148, a new RT inhibitor
A Q151L substitution, thought to be an intermediate to development of Q151M, emerged in selection experiments with the candidate nucleotide RT inhibitor GS-9148 [39] . Q151L virus had >threefold hypersusceptibility to zidovudine and tenofovir.
GS-9148 retains potent activity against virus harbouring the mutations K65R, L74V, M184V, and ≥4 thymidine analogue mutations. The mutation complex centred on the Q151M mutation has low-level resistance to GS-9148. Resistance to GS-9148 appears to follow two pathways in vitro: K70N to K70E to K70E plus D123N plus T165I, or Q151L plus S68N to Q151L plus L74I to Q151L plus L74I plus K70E/N plus L187F/M. Q151M has not emerged during prolonged selection with GS-9148.
To further characterize in vitro resistance to GS-9148, Kulkarni et al. [39] conducted dose-escalation experiments with the clonal HIV-1 strain LAI in MT2 cells and phenotyped site-directed mutants containing Q151L. They also performed molecular modelling of Q151L bound to GS-9148-diphosphate.
Q151L was selected after >100 days of exposure to GS-9148 and conferred 12-fold reduced susceptibility to GS-9148 and 17-fold resistance to GS-9131, the prodrug of GS-9148. Respective fold changes in susceptibility to GS-9148 were 7.7-fold and 8.5-fold with Q151L plus L74I, 32-fold and 50-fold with Q151L plus L74I plus K70E, and 36-fold and 49-fold with Q151L plus L74I plus K70E plus L187F. Q151L and Q151L plus L74I remained susceptible to abacavir, didanosine, emtricitabine, lamivudine and stavudine. Q151L and all the noted multiple mutations, including that substitution, were hypersusceptible to tenofovir and zidovudine. Q151L reverted to wild type under selection pressure from tenofovir or zidovudine and evolved to Q151M in the absence of drug. Lower resistance of Q151M than of Q151L to GS-9148 might explain failure of Q151M to emerge during prolonged in vitro selection with GS-9148.
Replication capacity of Q151L was 1.6% that of wildtype virus. L74I modestly restored replication capacity to 24% of wild-type replication, but additional mutations (K70E and L187F) did not further restore replication capacity. In these experiments, Q151M replication capacity was 78% of wild-type replication.
The crystal structure of wild-type RT bound to GS-9148-diphosphate showed that the 2′ fluoro moiety of GS-9148-diphosphate projects toward the Q151 residue. Modelling predicted steric hindrance for GS-9148 -diphosphate when bound to Q151L RT. Reduced susceptibility of GS-9148 to the Q151L mutant mapped to the 2′ fluoro moiety. Kulkarni et al. [39] suggested that hypersusceptibility of Q151L to tenofovir and zidovudine could be exploited by combining one of those agents with GS-9148.
Mechanisms of HIV-1 resistance to acyclovir detailed
Using a variety of biochemical approaches, Tchesnokov et al. [40] found evidence that HIV-1 might exploit two pathways to resistance to acyclovir [40] , an anti-herpes agent with activity against HIV-1 [41] . Earlier work showed that acyclovir selects for HIV-1 RT mutations V75I, M184V and T69N, with V75I as the dominant mutation [42] .
In work published online around the time of the workshop [43] , Tchesnokov et al. [40] assessed the inhibitory activity of CF2648, the monophosphorylated prodrug of acyclovir, against HIV-1 in MT4 cells. The mean ±sd 50% effective concentration of CF2648 rose from 3.4 ±2.8 µM against wild-type virus to 51 ±2.3 µM against V75I, a 15-fold increase.
The investigators hypothesized three possible effects of V75I on acyclovir: nucleoside reverse transcriptase inhibitor (NRTI) binding (as with M184V), NRTI incorporation (as with Q151M) or NRTI excision (as with T215Y). Pre-steady-state kinetics showed that V75I discriminates against the inhibitor at the level of incorporation, whereas binding of the inhibitor remains largely unaffected. In otherwise wild-type RT, V75I increased by 10-fold the selective advantage of the natural nucleotide over the inhibitor. Incorporated acyclovir monophospahte was vulnerable to excision in the presence of the pyrophosphate donor ATP. V75I compromised binding of the next nucleotide, which would otherwise offer some protection against excision.
Although V75I dicrimination against acyclovir at the level of incorporation appears to be the primary route of HIV-1 resistance to acyclovir, Tchesnokov et al. [40] proposed that diminished dead-end complex formation and increased efficiency of excision in the presence of thymidine analogue mutations suggest that acyclovir is also vulnerable to the excision mechanism of resistance.
Structure of RT/RNA:DNA in complex with tenofovir diphosphate
Higher-resolution crystal structures of HIV-1 RT crosslinked with RNA:DNA duplex and in complexes with tenofovir diphosphate or with the normal substrate dATP allowed Das et al. [44] to analyse structural differences between RNA:DNA versus DNA:DNA substrates and their interactions with RT.
The investigators determined the crystal structure of RT/RNA:DNA complexed with tenofovir disphosphate at a resolution of 2.57 Å, RNA:DNA complexed with dATP at a resolution of 2.6 Å, and RT/RNA:DNA binary complexes at a resolution of 3.2 Å. Tighter packing of RT molecules in the crystal lattice allowed these high resolutions, the highest reported for any RTnucleic acid structure. The researchers used the D498N mutant RT to prevent RNase H cleavage.
The high-quality electron density maps helped precisely position the nucleic acid, tenofovir-diphosphate, and dATP. Das et al. [44] determined that the RTbound RNA:DNA template-primer has structural differences from a bound DNA:DNA duplex. However, the binding of tenofovir-diphosphate and dATP at the polymerase active site in RT/RNA:DNA proved similar to their binding to RT/DNA:DNA complexes.
Novel mechanism for resistance to new NRTI, EFdA
Biochemical studies of the investigational NRTI 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) uncovered a novel mechanism of action for NRTIs, namely, the prevention of polymerase translocation [45] . This work by Marchand et al. [45] also found that triplemutant virus selected in serial passage studies confers resistance by two previously described mechanisms, discrimination and excision, that were thought to be mutually exclusive.
EFdA has activity against both wild-type HIV-1 and virus bearing clinically relevant mutations. Serial passage experiments defined sequential evolution of the mutations M184V (conferring 7.5-fold resistance), T165R (conferring 13-fold resistance with M184V) and I142V (conferring 21-fold resistance with M184V and T165R).
EFdA-monophosphate incorporation into the elongating DNA chain interrupted primer extension at the point of incorporation. EFdA-monophosphate at the 3′ end of the primer prevented RT translocation. Structural modelling suggested that M184V, the classic lamivudine and emtricitabine mutation, might cause steric hindrance with EFdA-triphosphate. Both M184V and T165R have decreased affinity for EFdA-triphosphate compared with wild-type virus, resulting in discrimination. T165R appears to increase discrimination by repositioning M184V. I142V improves excision efficiency of EFdA-monophosphate and thus enhances resistance. Together these three resistance mutations decrease viral replication capacity, probably because of reduced efficiency of nucleotide incorporation by mutant RT.
Because EFdA prevents polymerase translocation, Marchand et al. [45] dubbed this agent a translocationdefective RT inhibitor. They proposed that both discrimination and excision are needed to render HIV-1 highly resistant to EFdA.
New insights on HIV-1 replication from RT fidelity variants
Mapping of HIV-1 RT fidelity variants defined their location in three regions of the viral enzyme and could expand the understanding of enzyme-nucleic acid interactions that determine the quality of viral replication [46] .
Because RT lacks proofreading activity and replicates nucleic acids with low fidelity, Nissley et al. [46] developed a reverse transcription/fidelity assay that uncouples RT activity from viral replication. The system monitors RT activity in a retro-element with a reverse transcription indicator gene and measures fidelity via reversion of an inactive fidelity indicator gene.
RT variants affecting fidelity mapped to three regions: the fingers region, the p51 subunit β7/β8 loop, and the αA helix. Fingers region variants (V60A, A62T, I63K and F77S) probably alter nucleotide binding and specificity. The p51 subunit variants might exert a long-range effect on nucleotide discrimination at the active site, as Nissley et al. [47] and Ambrose et al. [48] demonstrated with RT mutation I132M, which confers hypersensitivity to NRTIs. Variants in the αA helix (C38S, E42K) could modify the interaction between RT and the template nucleic acid feeding into the active site. Biochemical and retrotransposition assays showed that several fidelity variants misincorporated nucleotides and that some might compromise viral replication.
Nissley et al. [46] proposed that fidelity variants might prove useful in comparing the evolution of resistance in low-fidelity RT viruses versus wild-type virus and in determining whether fidelity variants contribute to resistance.
Resistance to RT inhibitors: connection and RNase H domains
Resistance to zidovudine is greater with CRF01_AE than subtype B HIV-1 circulating recombinant form (CRF)01_AE already bearing thymidine analogue mutations exhibited substantially greater resistance to zidovudine than did HIV-1 subtype B bearing the same mutations [49] . The findings reinforce other research indicating that sequence differences between HIV-1 subtypes might lead to differences in susceptibility to antiretrovirals.
Mutations in the connection domain of HIV-1 subtype B RT increase resistance to zidovudine in virus harbouring thymidine analogue mutations (M41L, D67N, K70R, L210W, T215Y/F and K219Q/E) by upsetting the balance between nucleotide excision and template RNA degradation and thus allowing RT more time to carry out NRTI excision [50] [51] [52] . To see if connection domain mutations also alter resistance patterns in other HIV-1 subtypes, Delviks-Frankenberry et al. [49] analysed resistance to zidovudine in CRF01_AE, a CRF dominant in Southeast Asia. The investigators used extensive RT subdomain swapping and mutagenesis experiments to determine susceptibility of wild-type and treatmentexperienced CRF01_AE to zidovudine. CRF01_AE containing thymidine analogue mutations had 64-fold resistance to zidovudine compared with wild-type virus, whereas subtype B bearing the same mutations had 13-fold resistance to zidovudine. Greater resistance of CRF01_AE to zidovudine correlated with higher levels of zidovudine-monophosphate excision in both RNA and DNA templates.
The investigators determined that heightened resistance of CRF01_AE involved the 400 position in the RT connection domain. Wild-type CRF01_AE carries T400, whereas wild-type subtype B carries A400. Reversion to T400A in CRF01_AE reduced resistance to zidovudine from 64-fold to 6-fold and reduced zidovudine-monophosphate excision on both DNA and RNA templates. Those findings suggested that T400 increases CRF01_AE resistance to zidovudine at least in part by directly increasing the efficiency of zidovudinemonophosphate excision.
Delviks-Frankenberry et al. [49] believe these findings show that phenotypic testing of mixed subtypes (for example, mixing CRF01_AE pol with subtype B connection domain and RNase H) can underestimate actual levels of resistance to antiretrovirals. They proposed that resistance testing should rely on subtype-specific genotypic and phenotypic assays.
Mechanism of connection domain mutation resistance to zidovudine
Modelling studies suggested a plausible mechanism for how mutations at the N348 position of the HIV-1 RT connection domain confer resistance to zidovudine [53] . But this work did not suggest how the same mutations make HIV-1 resistant to nevirapine.
Earlier work showed that the N348I mutation in the RT connection domain makes HIV-1 resistant to zidovudine and nevirapine [54] , but that work did not suggest a potential mechanism. The mechanism is not immediately apparent because N348 lies distal to the DNA polymerase active site, the RNase H active site, the template/primer binding tract, and the NNRTIbinding pocket. To search for a potential mechanism, Radzio et al. [53] introduced the mutations N348A, N348E, N348I, N348L, N348Q and N348R into wildtype HIV-1 RT and purified the resulting recombinant enzymes. They used biochemical assays to calculate the DNA polymerase and RNase H activities of these enzymes, complementing these analyses with molecular modelling based on a novel model of HIV-1 RT in complex with an RNA/DNA template/primer.
Polymerase activity of N348A, N348I, N348L and N348Q enzymes proved equivalent to that of the wild-type RT. Because the N348E and N348R enzymes had significantly diminished DNA polymerase activity (P<0.01), the investigators excluded them from further analysis. N348I and N348L RTs significantly decreased RNase H cleavage activity, whereas cleavage was similar among wild-type RT, N348Q, and N348A. ATP-mediated excision assays determined that N348I RT had the greatest zidovudine-monophosphate excision efficiency, followed by N348L, N348Q and (equivalently) wild-type RT and N348A. Relative excision activity of each enzyme correlated with the RNase H activity of that enzyme.
The modelling analyses indicated that N348I, N348L and N348Q perturbed enzyme positioning on the β12-β13 loop in the p51 subunit of RT. Radzio et al. [53] suggested those findings imply a plausible structural mechanism for resistance of these mutant enzymes to zidovudine. N348I, N348A, N348Q and N348L mutant RTs all conferred approximately threefold to fourfold resistance to nevirapine. Resistance of these mutants to nevirapine did not correlate with RNase H activity or zidovudine-monophosphate excision activity, results suggesting that the mechanisms of N348 mutant resistance to nevirapine and zidovudine differ. Resistance to zidovudine appears to depend on an RNase-H-dependent mechanism, whereas the nevirapine resistance mechanism might be independent of RNase-H activity. Experiments focused on different connection domain mutations, described in the next section, implicated reduced RNase H cleavage in resistance to both NRTIs and NNRTIs.
Mechanism of dual resistance to NRTIs and NNRTIs
Work by Nikolenko et al. [55] produced evidence suggesting HIV-1 RT connection domain mutations share a similar mechanism in conferring resistance to NRTIs and NNRTIs: reduced RNase H cleavage.
These investigators previously showed that HIV-1 RT connection domain mutations in antiretroviralexperienced patients confer resistance to NRTIs [52] and NNRTIs [56] . Nikolenko et al. [55] hypothesized that the RNase H domain mutations D549N, Q475A and Y501A, which reduce RNase H activity, will increase resistance to NNRTIs. To test that hypothesis, they analysed resistance of these mutants to delavirdine, efavirenz, etravirine and nevirapine with a luciferase reporter gene-based susceptibility assay. D549N alone conferred resistance to nevirapine (fivefold) and delavirdine, but not to efavirenz or etravirine. Those findings are consistent with the decreased dissociation constant (Kd) of efavirenz (2.6 nM) relative to delavirdine (16.6 nM) and nevirapine (25 nM). Q475A and Y501A conferred high-level resistance to nevirapine (8.7-and 14.7-fold) and delavirdine (5.8-and 5.1-fold), moderate resistance to efavirenz (1.7-and 1.5-fold), and no resistance to etravirine.
Given these findings, Nikolenko et al. [55] further hypothesized that efavirenz and etravirine form a highaffinity dead-end complex with the RT-template/primer complex and that reduced RNase H activity does not promote significant dissociation of these two NNRTIs from the complex. As a result, virus bearing connection domain mutations remains susceptible to efavirenz and etravirine. To test these hypotheses, the investigators introduced efavirenz and etravirine binding pocket mutations to virus already harbouring the RNase H domain mutation D549N, figuring that virus with reduced RT affinity should remain sensitive to the resistance-enhancing effect of decreased RNase H activity. Combined with D549N, the efavirenz binding pocket mutation K103N increased resistance to efavirenz fivefold. With D549N, the etravirine mutations L100I/K103N/Y181C increased resistance more than sevenfold, whereas V179F/Y181C increased resistance more than threefold.
Nikolenko et al. [55] concluded that mutations that reduce RNase H activity can confer resistance to both NNRTIs and NRTIs, there is a balance between NNRTI binding/dissociation and RNA degradation, and NNRTI affinity to the RT-template/primer complex is crucial in determining the extent of resistance to NNRTIs conferred by mutations that reduce RNase H activity.
Connection and RNase H mutations is not tied to efavirenz failure in trial
The AIDS Clinical Trials Group (ACTG) study 5142 randomized previously untreated individuals to one of three regimens, including efavirenz and two NRTIs (zidovudine, stavudine, or tenofovir plus lamivudine) [57] . Brehm et al. [58] focused on 53 patients in whom the efavirenz regimen failed and who had pretreatment and failure plasma samples for analysis. ACTG 5142 defined failure as lack of HIV-1 RNA suppression by 1 log 10 copies/ml or suppression and rebound before week 32, or lack of suppression to <200 HIV-1 RNA copies/ml or suppression and rebound after week 32.
Sequencing the entire RT, the investigators found previously described polymerase domain mutations in 26 of 53 (49%) samples. Two polymerase domain mutations were significantly associated with failure: K103N (1.9% at baseline and 23% at failure; P=0.001) and M184I/V (1.9% at baseline and 15% at failure; P=0.016).Three connection domain mutations and two RNase H mutations proved >3% more frequent in failure samples than in pretreatment samples, but those associations lacked statistical significance (Table 3) .
Comparing baseline samples of 45 patients with virological failure and 144 patients without failure, Brehm et al. [58] 
043).
The investigators found one mutation, 334L, at a significantly greater prevalence in samples of 144 patients whose regimen did not fail (20 versus 7; P=0.040). They noted that these P-values were not corrected for multiple comparisons and should be interpreted with caution.
Brehm et al. [58] concluded that connection and RNase H mutations, with or without polymerase domain mutations, were not associated with failure of regimens containing two NRTIs plus efavirenz. They suggested that the lack of an association might reflect the sensitive definition of virological failure used in ACTG 5142 and/or the focus on a regimen containing efavirenz rather than nevirapine, which can select the N348I connection domain mutation.
No effect of connection domain mutations on response to etravirine
Although HIV-1 RT connection domain mutations might confer resistance to NNRTIs and NRTIs, those mutations had little measurable effect on virological response to etravirine-containing rescue regimens in the DUET trials [59] . Connection domain mutations did occur more frequently in pretreatment viral samples bearing thymidine analogue mutations.
The DUET trials randomized antiretroviralexperienced patients to receive 200 mg of the NNRTI etravirine twice daily or placebo plus darunavir/ritonavir and other antiretrovirals chosen by study physicians [60, 61] . Vingerhoets et al. [59] DUET baseline samples for prevalence of 17 connection domain mutations (L283I, E312Q, G333D/E, G335C/D, N348I, A360I/T/V, V365I, T369I, A371V, A376S, I393L and E399D/G). The investigators determined the effect of these mutations on susceptibility to etravirine and 24-week virological response (<50 HIV-1 RNA copies/ml) in 403 etravirine-treated patients with matched genotypic and phenotypic data who were not taking enfuvirtide for the first time and who did not discontinue treatment for reasons other than virological failure. They defined reduced virological response as <75% of the response in a subgroup of patients without baseline NNRTI resistance mutations. Eight connection domain mutations had a baseline prevalence >5%: L283I, G335D, N348I, A360V, V365I, A371V, A376S and E399D. All other connection domain mutations had a baseline prevalence <5%. Three connection domain mutations were associated with modestly reduced susceptibility to etravirine: G333D, T369I and A376S. The number of baseline connection domain mutations had no effect on susceptibility to etravirine, whereas more etravirine-related resistance mutations in pol increased resistance to the NNRTI. Overall rates of etravirine-related mutations were similar in patients with and without pretreatment connection domain mutations. Connection domain mutations did appear more often in baseline samples with more thymidine analogue mutations.
Virological response at week 24 was worse with than without G333D (40.0% versus 62.6%), G335D (50.0% versus 62.9%) or A376S (51.8% versus 64.0%). However, A376S was no longer associated with reduced response to etravirine in patients whose baseline virus had reduced susceptibility to etravirine (fold change in susceptibility >3) and darunavir (fold change >10). In patients without etravirine-related mutations in pol, neither G335D nor A376S correlated with a reduced virological response. Multivariate analysis accounting for baseline viral load and susceptibility to darunavir determined that adding connection domain mutations to a weighted genotypic score for etravirine did not improve the ability of that score to predict response to etravirine in the DUET trials.
Vingerhoets et al. [59] concluded that 15 of the 17 connection domain mutations analysed had no effect on virological response to etravirine in the DUET trials. The role of the two possible exceptions, G333D and G335D, remains to be determined.
Resistance to protease and integrase inhibitors
Role of Gag matrix and capsid in HIV-1 PI resistance and replication capacity
Mutations in the HIV-1 Gag matrix and capsid regions can confer resistance to PIs independently of Gag cleavage site mutations [62] . Three amino acid substitutions in matrix almost fully restored replication capacity of multidrug-resistant protease.
Much research has focused on the role of Gag cleavage site mutations in resistance to PIs, but relatively little work has addressed potential roles of Gag matrix and capsid in resistance. Work published online just after the workshop showed that Gag matrix and part of the capsid region are sufficient to restore replication capacity of virus bearing mutations in protease but not cleavage site mutations in Gag [63] .
In new work, Parry et al. [62, 63] used a single-cycle assay to evaluate susceptibility to PIs in two Gag region comparisons: matrix and partial capsid, and partial capsid and the remainder of Gag. The investigators used site-directed mutagenesis to identify substitutions in matrix and partial capsid that can restore replication capacity of virus bearing mutations in protease. Matrix and partial capsid represent the amino terminal half of Gag.
Parry et al. [62, 63] focused on 10 mutations in matrix (K30R, R76K, Y79F, T81A, T84V, E93D, I94V, D102E, H124N and N126S), an insertion in matrix (Q116TQ), and two mutations in partial capsid (I138M and S173M). Together these mutations conferred up to ninefold resistance to PIs in the absence of cleavage site mutations.
The position 116 insertion had minimal effect on viral replication capacity. By contrast, the matrix mutations R76K, Y79F and T81A combined restored replication capacity of virus already bearing classic mutations in protease from 5% of wild-type replication capacity to 73%. The T81A mutation by itself had only a modest effect in restoring replication capacity of virus harbouring mutations in protease. Noting that the mechanisms behind these findings remain unclear, the investigators recommended further study of PI resistance using fulllength Gag.
Resistance to integrase inhibitors

Raltegravir dissociation rate is linked to in vitro efficacy
Potent in vivo activity of the strand-transfer integrase inhibitor raltegravir did not correlate with raltegravir minimum concentration in a study of 332 antiretroviralexperienced patients enrolled in Phase 2 and 3 trials of this agent [64] . To identify correlates of raltegravir activity, Grobler et al. [65] designed experiments to address the hypothesis that a strand transfer integrase inhibitor that dissociates slowly from the integrase/ DNA complex needs to be present for only a fraction of the integration window to block viral replication [65] . Their study had two parts, which included mapping the integration window in cell culture, followed by measuring raltegravir binding kinetics in vitro.
Mapping the integration window involved two complementary experiments: a time-of-addition study and a washout study. In the time-of-addition study, the investigators infected HIV-1-GFP cells in multiple independent wells with 300 nM raltegravir at various times over 24 h. Counting GFP-expressing HIV-1-infected cells in each well at 48 h enabled Grobler et al. [65] to plot a steep decrease in infected cells per well beginning approximately 4 h after raltegravir addition through 12 h after addition. This inhibitory effect persisted through 48 h.
In the washout study, the investigators washed 300 nM raltegravir from HIV-infected cells in independent wells at various times over 24 h. Counting infected cells per well described a steeply rising curve beginning at approximately 4 h and trending into a plateau after approximately 12 h. Superimposing the time-of-addition curve and the washout curve defined an inhibition window extending from 4 h to 12 h after infection.
The investigators calculated raltegravir residence time on the integrase/DNA complex and dissociation time from that complex by measuring binding kinetics in a homogenous 3 H-raltegravir binding assay. Raltegravir residence time on wild-type integrase was equal to or greater than the half-life of the preintegration complex that viral DNA forms to integrate with host cell DNA. Raltegravir dissociation half-life on wildtype integrase at 37°C measured 7.3 h, compared with a half-life of 0.7 h on mutant N155H integrase. That 10-fold shorter half-life on mutant integrase could explain failure of raltegravir to control replication of virus bearing resistance mutations.
Grobler et al. [65] repeated these studies with MK-2048, an experimental strand transfer integrase inhibitor. This work indicated that MK-2048 has approximately a 32 h half-life on wild-type integrase and a 4 h half-life on N155H mutant integrase. Because the 4 h half-life on mutant virus approaches the half-life of raltegravir on wild-type virus, the investigators proposed that MK-2048 might exert more durable antiviral activity than raltegravir. They also suggested that a plausible explanation of raltegravir activity could lie in the finding that occupancy time of the drug on viral integrase exceeds the half-life of the pre-integration complex.
Selection study explains the emergence and fading of N155H with raltegravir
The N155H mutation in HIV-1 integrase might dominate the viral population early in the course of raltegravir failure, but continued selective pressure results in replacement of N155H with G140S plus Q148H/R/K or Y143R [66, 67] . To determine the reasons behind these sequential evolutionary pathways, Dam et al. [68] analysed seven site-directed mutants, including four single mutants (N155H, Q148H, G140S and E92Q) and three double mutants (Q148H plus G140S, N155H plus E92Q, and Q148H plus N155H) [68] . For each site-directed mutant, they measured viral replication capacity and viral susceptibility as fold change in IC 50 . They also calculated selective advantage profiles as the ratio of mutant to wild-type (NL4-3) infectivity as a function of raltegravir concentration in a single-cycle assay.
Among single mutants, mean fold change in IC 50 was highest for Q148H (78.0-fold), versus 31.5-fold for N155H, 3.7-fold for E92Q and 0.7-fold for G140S. By contrast, replication capacity was greater for N155H (59.9% of wild-type), G140S (61.3%) and E92Q (70.1%) than for Q148H (28.0%). Although resistance was more than 2× higher for Q148H than for N155H (mean fold change 78.0 versus 31.5), replication capacity of N155H doubled that of Q148H (59.9% versus 28.0% of wild-type replication capacity).
A selective index >1.0 indicates a selective advantage for a mutant. Among single mutants, N155H had the greatest selective advantage across raltegravir concentrations ranging from 1 to 500 nM (>1.5), whereas the selective advantage of Q148H and E92Q barely exceeded 1.0 (Figure 1 ). G140S had no selective advantage by this method of calculation. Among double mutants, G140S plus Q148H had the strongest selective advantage, N155H plus E92Q had a modest selective advantage and Q148H plus N155H had no selective advantage. In a study of resistance to raltegravir, N155H had the greatest selective advantage among single mutations in integrase, whereas Q148H and E92Q had smaller and narrower selective advantages. Dam et al. [68] proposed that these selective advantage curves explain the early preferential selection of N155H and its gradual replacement by genotypes including Q148H/K/R. The investigators noted that these observations are consistent with the dynamics of resistance genotypes during raltegravir failure in vivo.
A new type of integrase inhibitor is active against raltegravir-resistant virus QNL111, an integrase inhibitor that works by a mechanism different from strand-transfer inhibitors like raltegravir, showed activity against raltegravirresistant virus in cell studies and synergy with raltegravir against wild-type virus and single mutants [69] .
Raltegravir and the investigational integrase inhibitor elvitegravir impede viral replication by preventing integrase strand transfer in the nucleus of the infected cells. QNL111, a member of the quinoline family, inhibits HIV-1 integrase binding to its substrate, an early step in integration. Fluorescence anisotropy confirmed that QNL111 prevents integrase-DNA binding, whereas raltegravir acts on the preformed DNA-integrase complex. QNL111 antiviral activity measured as IC 50 in HeLa P4/R5 cells was 0.83 µM, and in MT4 cells was 0.89 µM.
Calculating fold change in susceptibility to QNL111 and raltegravir, Thibaut et al. [69] found that QNL111 retained activity against four single mutants that were resistant to raltegravir (Q148H, N155H, G140S and E92Q) and against two double mutants (E92Q/N155H and G140S/Q148H0).
The investigators calculated potential synergism between QNL111 and raltegravir by the combination index, with combination index <1 indicating synergism, combination index =1 indicating additivity, and combination index >1 indicating antagonism. The integrase inhibitors proved synergistic against wild-type virus (combination index =0.51 ±0.12) and the single mutants E92Q (combination index =0.18 ±0.02), G140S (combination index =0.30 ±0.17), Q148H (combination index =0.59 ±0.20), and N155H (combination index =0.47 ±0.16). Synergism of QNL111 and raltegravir was lost against the double mutants E92Q/N155H (combination index =1.09 ±0.49) and G140S/Q148H (combination index =1.37 ±0.19).
Global resistance and epidemiology
Models to predict response to second-line antiretrovirals without genotype
Two random forest models predicted response to second-line regimens without genotypic resistance testing in populations selected to represent patients in resourcepoor settings [70] . Verification of this approach could prove helpful in selecting second-line regimens in clinics without access to genotyping. However, the models do require viral load testing, which is also too expensive for many clinics in developing countries.
Revell et al. [70] developed two random forest computational models using data collected from >2,500 patients to predict the probability of reaching plasma viraemia <50 HIV-1 RNA copies/ml with second-line antiretroviral therapy. Random forest models combine the calculating power of thousands of individual decision trees.
These models were based on 8,514 treatment change episodes (TCEs) from >20 centres in high-income countries. TCEs were taken from patients selected to represent clinical practice in resource-poor countries: they had no experience with PIs, enfuvirtide, raltegravir or maraviroc, but could have PIs in their new regimen. Model 1 included 24 input variables, including baseline plasma viraemia and CD4 + T-cell count, three treatment history variables (zidovudine, lamivudine and any NNRTI), antiretrovirals in the new regimen, and follow-up time. Model 2 included 32 input variables, including variables in model 1 but with 11 individual antiretroviral treatment history variables instead of three.
Revell et al. [70] determined the predictive accuracy of the models using a training set of 8,114 TCEs and an independent test set of 400 TCEs. Training set patients began 248 different new regimens, which failed in 3,215 (40%) patients. Test set patients began 51 different new regimens, which failed in 205 (51%). The investigators calculated receiver operator characteristic (ROC) curves plotting predictions of the two models against actual responses to new regimens.
ROC area under the curve was high with both models, with an value of 0.879 for model 1 and 0.878 for model 2. Estimated accuracy of the models was 82% with model 1 and 82% with model 2, while respective sensitivity was 77% and 79% and specificity 86% and 85%. Baseline viral load was by far the most important input variable in model 2 (importance score 150.67), followed by time to follow-up (42.58), baseline CD4 + T-cell count (33.56), and current or former use of individual antiretrovirals.
The investigators programmed the models to predict responses to alternative three-drug regimens including older PIs (indinavir/ritonavir, saquinavir/ritonavir, lopinavir/ritonavir and nelfinavir) or all current PIs including new drugs (fosamprenavir/ritonavir, atazanavir/ritonavir and darunavir/ritonavir). When limited to older PIs, model 1 found effective alternative antiretrovirals for 46% of failures and model 2 found effective alternatives for 48% of failures. Those proportions increased only slightly when newer PIs were available, to 49% with model 1 and 52% with model 2.
Revell et al. [70] proposed that this approach could help optimize second-line regimens in settings with access to viral load testing but not genotypic resistance testing.
Differing PI mutation patterns in South African adults and children PI mutations were detectable upon failure of a first-line regimen containing lopinavir/ritonavir in South African children, but not upon failure of second-line lopinavir/ ritonavir in adults [71] . Instead NNRTI mutations, probably archived during first-line NNRTI failure, emerged in adults upon failure of lopinavir/ritonavir, an unusual pattern.
South African Department of Health guidelines call for lopinavir/ritonavir after an NNRTI regimen failure in adults and for first-line lopinavir/ritonavir in children, who are often exposed to the NNRTI nevirapine during or after birth. PI-related mutations are rare during early failure of a ritonavir-boosted PI in adults [72, 73] and older children [74, 75] , but they have been detected in children previously exposed to PIs [76] .
To analyse resistance patterns upon failure of a lopinavir/ritonavir regimen in children and adults, Hunt et al. [71] studied 45 children in whom first-line lopinavir/ritonavir with stavudine/lamivudine failed and 32 adults in whom second-line lopinavir/ritonavir failed with various NRTI combinations (zidovudine/didanosine in 18, lamivudine with zidovudine or stavudine in 9, zidovudine with tenofovir or abacavir in 4 and didanosine/ abacavir in 1).
The mean age of the children was 19 months (range 7-47) and treatment lasted 3-24 months. The mean age of the adults was 39 years (range .Resistance mutations were detectable upon failure in a slightly higher proportion of children than adults (80% versus 66%). The most common mutations in children were M184V in RT (70% of failures) and, in protease, V82A (>30% of failures), I54V (>20%) and M61I (<10%). NNRTI mutations were rare in children, but the K103N NNRTI mutation could be detected in 44% of adult failures and P225H in 16%. Overall, an NNRTI mutation could be detected in 53% of adults in whom lopinavir/ritonavir failed. M184V/I emerged in 28% of adult samples. Consistent with studies in other populations, no protease mutations emerged in adults upon failure of lopinavir/ritonavir.
Hunt et al. [71] noted a strong trend toward emergence of PI mutations in children receiving concurrent antimycobacterial medications (64%) than in those not taking antimycobacterials (28%; P=0.0665). Rifampicin is contraindicated in adults taking PIs because it greatly lowers PI concentrations.
In children, plasma viraemia at failure averaged 28,224 HIV-1 RNA copies/ml (range 1,170->75,000) but did not differ significantly between children with and without detectable resistance mutations (25,662 versus 42,292 copies/ml). In adults, plasma viraemia averaged 33,475 copies/ml and did not differ significantly between patients with and without detectable mutations (25,102 versus 57,993 copies/ml).
Hunt et al. [71] suggested that the high rate of PI mutations in children could reflect cotreatment for tuberculosis, and that differences between resistance patterns in adults and children might be partly explained by differences in adherence. Both possibilities require further study. The investigators did not speculate on why archived NNRTI mutations appeared to emerge upon lopinavir/ritonavir failure in adults.
Transmitted resistance is the only predictor of transmission clusters in Swiss men who have sex with men Almost one-third of transmitted drug resistance mutations (TDRs) among men who have sex with men (MSM) in Switzerland could be attributed to recently infected men [77] . Phylogenetic analysis determined that half of detected TDRs appeared in transmission clusters.
von Wyl et al. [77] analysed HIV-1 subtype B pol sequences from 430 MSM with an estimated date of infection from 2001 through 2004, calling these men tracked patients. The investigators used another 2,382 sequences from subtype B-infected MSM as controls. They defined a cluster as branches in a maximumlikelihood analysis including >2 sequences, including >1 tracked sequence, and with a bootstrap value >98/100. According to this definition, von Wyl et al. [77] identified clusters among 218 of 430 tracked sequences (51%) and among 206 of 2,382 control sequences (9%).
TDR as defined on the 2009 World Health Organization list [78] could be detected in 39 of 430 (9%) tracked sequences, of which 20 (51%) appeared in transmission clusters. Of the 39 TDRs among tracked sequences, 12 (31%) sequences in 6 clusters came from an antiretroviral-naive recently infected source (<1 year of documented seroconversion), 4 (10%) sequences in four clusters came from a chronically infected source, and 23 (59%) sequences had an unknown origin. Of these 23 sequences, 4 appeared in 4 clusters and 19 were not in clusters.
A sensitivity analysis limited to 1,773 antiretroviralnaive MSM and 148 recently infected MSM confirmed an approximate 9% prevalence of TDR, reflecting the 9% seen in the main analysis of 430 MSM. However, when the investigators divided these three populations into those involving primary-to-primary HIV-1 infection versus chronic-to-primary infection, they found a lower TDR prevalence in the primary-to-primary than in the chronic-to-primary subgroups of the recently infected MSM, but a higher TDR prevalence in the primaryto-primary than in the chronic-to-primary subgroups of the antiretroviral-naive MSM. von Wyl et al. [77] concluded that TDR estimates in their analysis varied widely depending on the denominator and thus samples for phylogenetic analysis should be selected with care.
Prevention of mother-to-child transmission, minor variants and HIV-1 resistance
Extended zidovudine lowers nevirapine resistance risk in HIV-1-infected infants Infants infected with HIV in utero who received extended zidovudine plus extended nevirapine for prophylaxis before HIV-1 diagnosis had a lower rate of nevirapine resistance mutations than infants who received only extended nevirapine prophylaxis [79] . The protective effect of extended zidovudine did not hold in HIV-1-infected infants who continued prophylaxis for prevention of mother-to-child transmission (PMTCT) beyond 6 weeks of age.
Approximately 70% of HIV-1-infected women in the PEPI-Malawi study received single-dose nevirapine (sdNVP) during labour [80] . Infants were randomized to sdNVP plus 1 week of zidovudine (the control regimen), that regimen plus daily nevirapine, or the control regimen plus daily nevirapine and zidovudine up to 14 weeks of age. Prophylaxis was stopped before 14 weeks in infants diagnosed with HIV-1 infection. The trial found no significant difference in HIV-1 incidence between infants receiving both extended nevirapine and zidovudine and those receiving only extended nevirapine, but both extended regimens were superior to the control regimen. Malawi PMTCT guidelines recommend sdNVP for the mother, if possible, and sdNVP plus 1 week of zidovudine for the infant. The rationale for extended zidovudine is both to reduce the risk of HIV-1 transmission and to lower the risk of resistance to nevirapine.
Lidstrom et al. [79] analysed resistance results from infants infected in utero in PEPI-Malawi to see if mutation rates differed between the 82 infants who received extended zidovudine and extended nevirapine and the 79 who received only extended nevirapine. Genotyping results were available for 45 infants in the nevirapine plus zidovudine group and 43 in the nevirapine-only group. At 14 weeks, nevirapine resistance mutations could be detected in 28 of the 45 nevirapine plus zidovudine samples (62%) and 37 of the 43 nevirapine-only samples (86%), a significant difference (P=0.015).
Among infants with genotyping results, prophylaxis was stopped at a median of 6 weeks (range 1-14) in both groups. In preliminary week-14 results, nevirapine resistance mutations could be detected in 10 of 18 (56%) infants on extended nevirapine plus zidovudine and in 20 of 22 (91%) on extended nevirapine alone who stopped prophylaxis by week 6. At week 14, there was no significant difference in mutation rates between the two groups in the subset of infants who continued prophylaxis beyond 6 weeks.
The investigators proposed that if HIV-1 infection status cannot be determined in infants before starting extended nevirapine for PMTCT, then adding extended zidovudine might help reduce the risk of nevirapine resistance mutations in infants infected with HIV-1 despite prophylaxis.
NNRTI failure without detectable pretreatment mutations in plasma after sdNVP Women exposed to sdNVP but without mutations detectable in plasma had almost a doubled risk of virological failure on an NNRTI-based regimen compared with sdNVP-unexposed women [81] . This finding in a retrospective analysis of Zambian women suggested mutations in some sanctuary site could affect response to an NNRTI regimen after sdNVP exposure.
Johnson et al. [81] studied 427 HIV-1-infected Zambian women beginning antiretroviral therapy, 162 of them exposed to sdNVP and 265 not exposed; 97% were infected with HIV-1 subtype C. No women had taken any antiretrovirals before starting a nevirapine-based regimen or (if receiving treatment for tuberculosis) an efavirenz-based regimen. The investigators retrospectively tested pretreatment samples for nevirapine-associated mutations with standard bulk sequencing, and they used sensitive real-time PCR assays to evaluate the same samples for low levels of the NNRTI mutations K103N, V106M/I, Y181C and G190A.
Among the 162 women exposed to sdNVP, mutations detectable by bulk sequencing or real-time PCR before antiretroviral therapy began were significantly more common in women evaluated <6 months after sdNVP exposure: 41% with bulk sequencing, 57% with real-time PCR (P<0.001 for both versus >6 months after sdNVP exposure). Following 7-12 months of sdNVP exposure, mutation detection rates were 3% with bulk sequencing and 23% with real-time PCR. Detection rates >12 months after sdNVP exposure were 8% with bulk sequencing and 22% with real-time PCR. Mutation prevalence in randomly selected women not exposed to sdNVP was nominal at 2%.
Defining antiretroviral failure as >400 HIV-1 RNA copies/ml at treatment week 24 or 48, Johnson et al. [81] recorded a 50% failure rate among women with mutations detectable by bulk sequencing (14 of 28) and a 30% failure rate among women with mutations detectable only by real-time PCR (16 of 53). Most failures occurred among women who began antiretroviral therapy within 6 months of sdNVP: 11 of 14 (79%) in the bulk-sequencing group and 11 of 16 (69%) in the real-time PCR group. But a substantial proportion of women experienced virological failure when beginning antiretroviral therapy >12 months after sdNVP exposure: 2 of 14 (14%) in the bulk-sequencing group and 3 of 16 (19%) in the real-time PCR group. Adherence to antiretroviral regimens was estimated at >96%.
Detectable V106M (n=4) or V179D (n=5) before antiretroviral therapy was not associated with virological failure. Among women with pretreatment resistance mutations, failure rates did not differ significantly between those with >100,000 versus <100,000 HIV-1 RNA copies/ml (P=0.52), <200 versus >200 CD4 + T-cells/mm 3 (P=0.16), or >1 NNRTI mutation versus 1 NNRTI mutation (P=0.3). Compared with sdNVPexposed women with no detectable mutations, those with mutations detectable by bulk sequencing or bulk sequencing plus real-time PCR had a significantly higher failure rate (P=0.021 and P=0.024, respectively).
Nevertheless, NNRTI-based therapy was 1.7× more likely to fail in women exposed to sdNVP but without mutations detectable by either assay than in women not exposed to sdNVP (26% versus 15%; P=0.02). Antiretroviral therapy response rates did not differ significantly between women with only minority mutations detected by real-time PCR and women with no detectable mutations (18% versus 27%; P=0.3). Failure of NNRTI-based antiretroviral therapy was significantly more likely when women began treatment within 6 months of sdNVP exposure, but 26 of 46 (57%) sdNVP-exposed women in whom treatment failed had no detectable resistance mutations in plasma before beginning therapy.
Johnson et al. [81] proposed that the especially high failure rate in sdNVP-exposed women, even in the absence of detectable resistance, suggests there could be resistance mutation sanctuaries outside plasma that might at least transiently affect response to antiretroviral therapy. The study summarized next investigated one such sanctuary.
Mutations in HIV-1 DNA raise failure risk after sdNVP Low-frequency NNRTI mutations detected in HIV-1 DNA after sdNVP and just before a nevirapine-based regimen raised the risk of virological failure on that regimen [82] . Earlier studies correlated sdNVP exposure with treatment outcome on nevirapine-based therapy [83] [84] [85] , although one of those studies found no association between mutations detected by standard sequencing in plasma-derived HIV-1 RNA 10 days after delivery [83] . By contrast, another study appeared to show an association between virological response and mutations detected in plasma by standard sequencing immediately before antiretroviral therapy [85] .
Wagner et al. [82] investigated the predictive value of low-concentration NNRTI mutations in HIV-1 DNA detected in women exposed to sdNVP before beginning a nevirapine-based regimen. The investigators used an oligonucleotide ligation assay (OLA) to probe for mutations in 269 women originally assessed in one of the earlier studies [83] . OLA searched for three mutations (K103N, Y181C and G190A) present at a level >5% in 100 copies of HIV-1 DNA. Among 181 women with OLA results, 148 had been exposed to sdNVP and 38 had received placebo in the original randomized trial.
OLA could not detect any of the three NNRTI mutations in the placebo recipients, whereas 38 of 146 sdNVP-exposed women (26%) had detectable mutations (K103N in 13%, Y181C in 5% and G190A in 19%). Defining virological failure as >50 HIV-1 RNA copies/ml of plasma 6-18 months after treatment began, Wagner et al. [82] found more than a doubled risk of failure in women with >1 NNRTI mutation (adjusted hazard ratio [AHR] 2.47, 95% CI 1.34-4.54, P=0.004). There were two other independent predictors of virological failure: pretreatment plasma HIV-1 RNA >4.77 log 10 copies/ml, the median value in this population (AHR 2.39, 95% CI 1.27-4.47; P=0.007) and time from sdNVP<6 months (AHR 3.20, 95% CI 1.65-621; P=0.001).
Kaplan-Meier analysis defined a significant difference in failure rate when comparing 38 sdNVP-exposed women with >1 mutation and 110 sdNVP-exposed women with no detectable mutations (P<0.0001). Both sdNVP-exposed groups had higher failure rates than the placebo group, although the difference between the placebo group and sdNVP-exposed women without detectable mutations was not statistically significant. Wagner et al. [82] proposed that their findings suggest HIV-1 DNA resistance testing with a sensitive assay might be an effective pretreatment resistance testing strategy.
Failure threshold proposed for low-frequency K103N
A pretreatment K103N NNRTI mutation population >2,000 copies/ml on a highly sensitive assay correlated with virological failure in antiretroviral-naive patients starting an efavirenz-containing triple-drug regimen [86] . This is the first study suggesting a failure threshold for low-frequency pretreatment resistant virus. Earlier studies yielded conflicting results on the virological effect of low-frequency K103N [87] [88] [89] .
Goodman et al. [86] analysed K103N mutation patterns and virological failure in study GS-01-934, which compared efavirenz plus tenofovir/emtricitabine to efavirenz plus zidovudine/lamivudine in 509 previously untreated patients [90] . The investigators excluded 22 patients from the original analysis because standard sequencing detected K103N before treatment. Defining virological failure as confirmed HIV-1 RNA>400 copies/ml at week 144 or early discontinuation, the researchers counted 29 failures in the zidovudine/lamivudine group, 18 (62%) of them with K103N at failure by population sequencing, and 19 (42%) failures in the tenofovir/emtricitabine group, 8 of them with K103N.
The new study tested all baseline samples for minor populations of K103N with an allele-specific (AS)-PCR assay that can detect variants representing >0.5% of a viral population. AS-PCR detected pretreatment K103N in 16 patients, 11 of them randomized to zidovudine/ lamivudine and 5 to tenofovir/emtricitabine. Overall 5 (45%) patients with pretreatment minority K103N in the zidovudine/lamivudine group and 1(20%) in the tenofovir/emtricitabine met 144-week virological failure criteria. In the zidovudine/lamivudine group, failure was significantly more likely with than without minority K103N (5 of 11 versus 24 of 226; P=0.005).
Goodman et al. [86] calculated K103N copy number as the population percentage of K103N multiplied by baseline plasma viraemia. K103N copy number appeared to distinguish patients with virological failure from those who responded to efavirenz-containing therapy. Among patients with virological failure, K103N copies ranged from 1,254 to 16,071 copies/ml, compared with 51 to 5,535 copies/ml among virological responders. Among 6 patients with ≥2,000 K103N copies/ml before treatment, 5 had virological failure, compared with 1 of 10 who had <2,000 copies/ml (P=0.008). Multivariate logistic regression determined that K103N ≥2,000 copies/ml raised the risk of virological failure nearly 50× (OR 47.4, 95% CI 5.2-429.2; P=0.0006). In the same analysis, K103N <2,000 copies/ ml, baseline HIV-1 RNA>100,000 copies/ml, baseline CD4 + T-cell count ≥200 cells/mm 3 and treatment arm did not predict failure.
Overall, only 6 of 476 (1.3%) patients had pretreatment K103N>2,000 copies/ml, as detected by AS-PCR. As a result, Goodman et al. [86] called for further study to establish the clinical relevance of threshold levels of transmitted resistant virus.
Response to boosted PIs in patients with transmitted resistance
Most transmitted resistance mutations had little effect on response to a first-line regimen including ritonavirboosted atazanavir or lopinavir in the CASTLE trial [91] . Multiple transmitted NRTI mutations at low and high abundance specific to the backbone did appear to affect virological response at 48 weeks, but numbers of patients in these analyses were small. CASTLE randomized 883 antiretroviral-naive patients on five continents to once-daily atazanavir/ ritonavir or twice-daily lopinavir/ritonavir, both with tenofovir/emtricitabine [92] . Approximately three quarters of patients in each study arm had <50 HIV-1 RNA copies/ml at 48 weeks. The new analysis was a casecontrol comparison of all 53 patients with virological failure at week 48 and 95 randomly selected responders matched by baseline CD4 + T-cell count and plasma viraemia. Lataillade et al. [91] used ultradeep sequencing to search for resistance mutations in pretreatment samples, defining transmitted mutations by the 2009 World Health Organization list [78] . The assay detection limit was set at >1% of the viral population.
Of 53 patients with virological failure at week 48, the assay was successful in 51, including 32 with subtype B HIV-1 and 19 with another HIV-1 subtype. Of the 95 patients without virological failure, the assay succeeded in 90 samples, including 54 from patients with subtype B and 36 from patients with other subtypes. Overall, 43 of 141 (30.5%) sequenced samples carried at least one resistance mutation, including 22 (15.6%) samples in which mutations represented <20% of the viral population and 21 (14.9%) samples with at least one mutation representing ≥20% of the population (the percentage usually cited as the cutoff for standard sequencing). A total of 22 of 141 (15.6%) isolates carried only mutations making up <20% of the population. Mutation prevalence did not differ in a comparison of subtype B and non-B isolates.
A total of 14 of 141 (9.9%) isolates harboured a PI mutation, 16 (11.3%) carried an NNRTI mutation and 35 (24.8%) had an NRTI mutation. Equivalent proportions of NRTI mutations were above and below the 20% population cutoff. Higher proportions of NNRTI mutations (12 versus 4) and PI mutations (11 versus 3) represented <20% of the viral population. Overall, 18 (12.8%) patients had multiclass resistance mutations.
Pretreatment infection with any mutation or with a mutation from a specific antiretroviral class did not jeopardize 48-week virological response in these patients. Overall, among the 43 patients with any mutation, 30 were virological responders and 13 had virological failure. Among the 14 patients with a pretreatment PI mutation, 13 were virological responders. In total, 10 of the 14 patients with a pretreatment PI mutation had only one such mutation. Most transmitted PI mutations were solitary (10 of 14), had low Stanford HIV database scores, and were at low levels in the pretreatment viral population (11 of 14) .
Of the 35 patients with NRTI mutations, 26 had thymidine analogue mutations (M41L, D67N, K70R, L210W, T215Y/F and K219Q/E), 9 had M184I/V and 2 had K65R. Among the nine patients with M184I/V, seven (<20%) had low-frequency populations of that mutation. Six of these nine experienced virological failure, four of whom also had thymidine analogue mutations and one of whom also had K65R. All three patients with M184V and multiple thymidine analogue mutations had virological failure. Among all 16 patients with multiple thymidine analogue mutations, 7 had virological failure. Failure rates with extensive pretreatment NRTI mutations did not differ significantly between patients taking atazanavir versus lopinavir.
